RIBOMIC enters license agreement with AJU Pharma for RBM-007 in age-related macular degeneration
Upon execution of this Agreement, AJU will obtain the exclusive license to develop and sell the Product containing RBM-007 (the “Product”) in the Territory. RIBOMIC will receive an